Current drug targets最新文献_第6页

Two Decades Rituximab Therapy in Anti-Neutrophil Cytoplasmic Antibody Associated Vasculitis. 利妥昔单抗治疗抗中性粒细胞胞浆抗体相关性血管炎二十年。

IF 3 4区医学

Current drug targets Pub Date : 2025-01-01 DOI: 10.2174/0113894501323529240910015912

Mohammad Amin Habibi, Sajjad Ahmadpour, Javad Tafaroji, Seyed Mohammad Eazi, Poriya Minaee, Yousef Mohammadpour, Soheil Tavakolpour

{"title":"Two Decades Rituximab Therapy in Anti-Neutrophil Cytoplasmic Antibody Associated Vasculitis.","authors":"Mohammad Amin Habibi, Sajjad Ahmadpour, Javad Tafaroji, Seyed Mohammad Eazi, Poriya Minaee, Yousef Mohammadpour, Soheil Tavakolpour","doi":"10.2174/0113894501323529240910015912","DOIUrl":"10.2174/0113894501323529240910015912","url":null,"abstract":"Remission failure and relapse numerate as one of the main problems in patients with antineutrophil cytoplasmic antibody-associated vasculitis (AAVs). The need for new agents that provide effective and safe induction accompanied by sustained remission seems to be urgent in clinical care. The efficacy and safety of rituximab (RTX) for AAVs therapy has been reported in various studies. RTX therapy offers several advantages to treating AAVs patients compared to other therapeutic approaches including reduction of Glucocorticoids (GCs) and conventional Immunosuppressive therapy (IST) usage during both the induction of remission and maintenance phases. This reduction can lead to a lower rate of serious complications making RTX therapy a safer option. It seems that RTX may provide improved clinical outcomes in these patients mediated via B-lymphocyte depletion, Proteinase 3-antineutrophilic cytoplasmic antibody (PR3-ANCA), and myeloperoxidase-antineutrophilic cytoplasmic antibody (MPO-ANCA) titers reduction. In this regard, some uncertainties have been reported to validate the association between such depletion and clinical improvement, as suggested by other sources of autoreactive B cells that did not target with RTX. Due to the prolonged B cell depletion, fixed intervals and adjusted dosage of RTX may be required in patients with AAVs. In this narrative review, we aimed to insight better understand regarding the efficacy of RTX for effective induction and sustained remission in patients with AAVs. It seems that discovering new biomarkers predicting relapse in AAVs patients can lead to future targeted therapy.","PeriodicalId":10805,"journal":{"name":"Current drug targets","volume":" ","pages":"73-87"},"PeriodicalIF":3.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142343147","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Signaling Dynamics in Osteogenesis: Unraveling Therapeutic Targets for Bone Generation. 骨生成中的信号动力学：揭示骨生成的治疗靶点。

IF 3 4区医学

Current drug targets Pub Date : 2025-01-01 DOI: 10.2174/0113894501359782241216082049

Xue D Yang, Christopher L Haga, Donald G Phinney

{"title":"Signaling Dynamics in Osteogenesis: Unraveling Therapeutic Targets for Bone Generation.","authors":"Xue D Yang, Christopher L Haga, Donald G Phinney","doi":"10.2174/0113894501359782241216082049","DOIUrl":"10.2174/0113894501359782241216082049","url":null,"abstract":"Diseases affecting bone encompass a spectrum of disorders, from prevalent conditions such as osteoporosis and Paget's disease, collectively impacting millions, to rare genetic disorders including Fibrodysplasia Ossificans Progressiva (FOP). While several classes of drugs, such as bisphosphonates, synthetic hormones, and antibodies, are utilized in the treatment of bone diseases, their efficacy is often curtailed by issues of tolerability and high incidence of adverse effects. Developing therapeutic agents for bone diseases is hampered by the fact that numerous pathways regulating bone metabolism also perform pivotal functions in other organ systems. Consequently, the selection of an appropriate target is a complicated process despite the significant demand for novel medications to address bone diseases. Research has shown the role of various cell signaling pathways, including Wnt, PTHR1, CASR, BMPRs, OSCAR, and TWIST1, in the regulation of osteogenesis, bone remodeling, and homeostasis. Disruptions in bone homeostasis can result in decreased bone density and the onset of osteoporosis. There remains a need for the development of drugs that can enhance bone remodeling with improved side effects profiles. The exploration of promising targets to stimulate bone formation has the potential to significantly advance the field of bone-related medical care, thereby improving the quality of life for millions. Additionally, a deeper understanding of anabolic and catabolic pathway mechanisms could enable future studies to explore synergistic effects between unrelated pathways. Herein, we explore potential drug targets that may be exploited therapeutically using small molecule agonists or antagonists to promote bone remodeling and discuss their advantages and limitations.","PeriodicalId":10805,"journal":{"name":"Current drug targets","volume":" ","pages":"350-366"},"PeriodicalIF":3.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142945986","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

MT1JP: A Pivotal Tumor-Suppressing LncRNA and its Role in Cancer Progression and Therapeutic Potential. MT1JP：一个关键的肿瘤抑制LncRNA及其在癌症进展和治疗潜力中的作用。

IF 3 4区医学

Current drug targets Pub Date : 2025-01-01 DOI: 10.2174/0113894501365982250119150404

Haodong He, Jingjie Yang, Wenjin Peng, Moyu Li, Meiyan Shuai, Faming Tan, Zheng Cao, Chengfu Yuan

{"title":"MT1JP: A Pivotal Tumor-Suppressing LncRNA and its Role in Cancer Progression and Therapeutic Potential.","authors":"Haodong He, Jingjie Yang, Wenjin Peng, Moyu Li, Meiyan Shuai, Faming Tan, Zheng Cao, Chengfu Yuan","doi":"10.2174/0113894501365982250119150404","DOIUrl":"10.2174/0113894501365982250119150404","url":null,"abstract":"Metallothionein 1J pseudogene (MT1JP) is a long non-coding RNA (lncRNA) that functions as a tumor suppressor in various malignancies. Reduced MT1JP expression is associated with increased tumor proliferation, migration, invasion, epithelial-mesenchymal transition (EMT), and treatment resistance in nine cancers, such as gastric cancer, intrahepatic cholangiocarcinoma, hepatocellular carcinoma, and breast cancer. Mechanistically, MT1JP acts as a competitive endogenous RNA (ceRNA) to regulate oncogenic microRNAs (miRNAs), including miR-92a-3p, miR-214-3p, and miR-24-3p. This regulation restores tumor suppressor genes, such as FBXW7, RUNX3, and PTEN, thereby disrupting oncogenic pathways, including PI3K/AKT, Wnt/β- catenin, and p53, promoting apoptosis, and inhibiting tumor progression. Clinically, MT1JP expression correlates with tumor grade, differentiation, TNM stage, lymph node metastasis, and patient prognosis, suggesting its potential as a diagnostic and prognostic biomarker. Furthermore, its therapeutic potential in RNA-based treatments has attracted significant attention. Despite these findings, questions remain regarding its role in epigenetic regulation, transcriptional control, and RNA delivery. This review explores the molecular mechanisms underlying MT1JP, highlighting its clinical relevance and potential as a therapeutic target. Future research should focus on elucidating its role in epigenetic regulation, overcoming challenges in therapeutic delivery, and validating its utility as a biomarker for different cancers. MT1JP holds promise for advancing precision oncology by providing innovative approaches for cancer diagnosis and treatment.","PeriodicalId":10805,"journal":{"name":"Current drug targets","volume":" ","pages":"394-409"},"PeriodicalIF":3.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143022508","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Fibroblast Growth Factors: Roles and Emerging Therapeutic Applications. 成纤维细胞生长因子：作用和新兴的治疗应用。

IF 2.5 4区医学

Current drug targets Pub Date : 2025-01-01 DOI: 10.2174/0113894501351461250301072444

Gaëtane Ternier, Kaynat Shahzad, Oshadi Edirisinghe, Patience Okoto, Zeina Alraawi, Shivakumar Sonnaila, Phuc Phan, Paul D Adams, Suresh K Thallapuranam

引用次数: 0

Pharmacological and Therapeutic Potential of a Natural Flavonoid Icariside II in Human Complication. 一种天然黄酮类Icariside II在人类并发症中的药理和治疗潜力。

IF 3 4区医学

Current drug targets Pub Date : 2025-01-01 DOI: 10.2174/0113894501329810241117231839

Dhirendra Singh, Randhir Singh

{"title":"Pharmacological and Therapeutic Potential of a Natural Flavonoid Icariside II in Human Complication.","authors":"Dhirendra Singh, Randhir Singh","doi":"10.2174/0113894501329810241117231839","DOIUrl":"10.2174/0113894501329810241117231839","url":null,"abstract":"Emerging challenges to human health necessitate a coordinated effort to find both preventative and therapeutic techniques, with natural products at the forefront of attempts to gain novel medicines and minimize disease transmission and related death. The medicinal potential of chemicals contained in plants has been known for centuries, leading to its use in homes and clinics for the treatment of numerous disorders. Despite global advancements, plant-based medicines continue to be utilized to treat various pathological illnesses or as alternatives to contemporary pharmaceuticals. The safety and low toxicity of natural products have led to their increasing acceptability for the prevention or treatment of many ailments. Flavonoids are biologically active compounds that are classified as polyphenols, which are a type of secondary metabolite found in all plants. Icariside II (ICA-II) is one of the secondary metabolites that belong to the flavonoid category of phytochemicals and is present in Epimedium brevicornum Maxim. In recent years, ICA-II has been discovered to show anti-inflammatory, antioxidant, anticancer, renal protecting, and cardiac protective effects, as well as several other biological characteristics. This review is focused on the exploration of the pharmacological activities of ICA-II. ICA-II is considered a prospective candidate for future clinical investigations due to a number of therapeutic properties.","PeriodicalId":10805,"journal":{"name":"Current drug targets","volume":" ","pages":"320-330"},"PeriodicalIF":3.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142930766","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Targeting SERCA2 in Anti-Tumor Drug Discovery. 在抗肿瘤药物研发中靶向 SERCA2。

IF 3 4区医学

Current drug targets Pub Date : 2025-01-01 DOI: 10.2174/0113894501325497240918042654

Wanqian Song, Qiuju Zhang, Zhiyong Cao, Guo Jing, Tiancheng Zhan, Yongkang Yuan, Ning Kang, Qiang Zhang

引用次数: 0

Repurposing Nano Curcumin: Unveiling its Therapeutic Potential in Diabetic Nephropathy. 纳米姜黄素的再利用：揭示其治疗糖尿病肾病的潜力。

IF 3 4区医学

Current drug targets Pub Date : 2025-01-01 DOI: 10.2174/0113894501326054241126043554

Rarchita Sharma, Yogesh Mali, Yogeeta O Agrawal, Vinit V Agnihotri, Sameer N Goyal

{"title":"Repurposing Nano Curcumin: Unveiling its Therapeutic Potential in Diabetic Nephropathy.","authors":"Rarchita Sharma, Yogesh Mali, Yogeeta O Agrawal, Vinit V Agnihotri, Sameer N Goyal","doi":"10.2174/0113894501326054241126043554","DOIUrl":"10.2174/0113894501326054241126043554","url":null,"abstract":"Currently, Diabetic Nephropathy (DN) stands as the predominant global cause of endstage renal disease. Many scientists believe that diabetes will eventually spread to pandemic levels due to the rising prevalence of the disease. While the primary factor leading to diabetic nephropathy is vascular dysfunction induced by hyperglycemia, several other pathological elements, such as fibrosis, inflammation, and oxidative stress, also contribute to the progression of the disease. The primary targets of current DN therapy approaches are the underlying abnormalities of hypertension and glucose. With several targets and fewer side effects, curcumin is a commonly utilized antioxidant in DN. The present study emphasizes the critical role of oxidative stress and inflammation in the development of diabetic nephropathy. It reveals how these factors induce damage in key kidney cell types, highlighting their potential as therapeutic targets for this disease. In addition, by concentrating on Nrf2, SIRT1, HMGB1, NF-κB, and NLRP3 of curcumin, has strong anti- inflammatory and antioxidant characteristics. This review describes the role of curcumin in the therapeutic application of diabetic nephropathy. In this attempt, we tried to elaborate on the bench-to-bedside aspects of curcumin in DN, including clinical and preclinical investigations. The rationales of curcumin's mechanisms in alleviating symptoms of the DN were discussed. Curcumin could serve as the potential therapeutic agent for the patient seeking to recover from DN.","PeriodicalId":10805,"journal":{"name":"Current drug targets","volume":" ","pages":"298-319"},"PeriodicalIF":3.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142945622","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Enhancements in Parkinson's Disease Management: Leveraging Levodopa Optimization and Surgical Breakthroughs. 加强帕金森病的治疗：利用左旋多巴优化和手术突破。

IF 3 4区医学

Current drug targets Pub Date : 2025-01-01 DOI: 10.2174/0113894501319817240919103802

Ritika Sharma, Avneet Kour, Hitesh Kumar Dewangan

{"title":"Enhancements in Parkinson's Disease Management: Leveraging Levodopa Optimization and Surgical Breakthroughs.","authors":"Ritika Sharma, Avneet Kour, Hitesh Kumar Dewangan","doi":"10.2174/0113894501319817240919103802","DOIUrl":"10.2174/0113894501319817240919103802","url":null,"abstract":"Parkinson's disease (PD) is a complex neurological condition caused due to inheritance, environment, and behavior among various other parameters. The onset, diagnosis, course of therapy, and future of PD are thoroughly examined in this comprehensive review. This review also presents insights into pathogenic mechanisms of reactive microgliosis, Lewy bodies, and their functions in the evolution of PD. It addresses interaction complexity with genetic mutations, especially in genes such as UCH-L1, parkin, and α-synuclein, which illuminates changes in the manner dopaminergic cells handle proteins and use proteases. This raises the improved outcomes and life quality for those with PD. Potential treatments for severe PD include new surgical methods like Deep Brain Stimulation (DBS). Further, exploration of non-motor manifestations, such as cognitive impairment, autonomic dysfunction, and others, is covered in this review article. These symptoms have a significant impact on patients' quality of life. Furthermore, one of the emerging therapeutic routes that are being investigated is neuroprotective medicines that aim to prevent the aggregation of α-synuclein and interventions that modify the progression of diseases. The review concludes by stressing the dynamic nature of PD research and the potential game-changing impact of precision medicines on current approaches to therapy.","PeriodicalId":10805,"journal":{"name":"Current drug targets","volume":" ","pages":"17-32"},"PeriodicalIF":3.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142343143","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

New Advances in Drug Research for Myopia Control in Adolescents. 青少年近视控制药物研究新进展

IF 3 4区医学

Current drug targets Pub Date : 2025-01-01 DOI: 10.2174/0113894501359801250102055530

Yu Liu, Yalong Dang

{"title":"New Advances in Drug Research for Myopia Control in Adolescents.","authors":"Yu Liu, Yalong Dang","doi":"10.2174/0113894501359801250102055530","DOIUrl":"10.2174/0113894501359801250102055530","url":null,"abstract":"Background: Myopia is one of the most common eye diseases worldwide, with an increasing incidence observed in recent years. Globally, effective treatments for myopia have been extensively explored. In recent years, research on drugs for the treatment of myopia has become a popular topic in ophthalmology, with some breakthroughs having been achieved. Compared with surgical treatment, drug treatment is easier for people to accept. Although the efficacy of some drugs in delaying the development of myopia has been confirmed, the mechanism and site of action of some drugs are still not completely clear.Objective: In this study, we review the recent related research on drug therapy for myopia at home and abroad, describe the mechanism of various drugs in treating myopia, evaluate their clinical application value, and identify existing problems.Results: These drugs include atropine, a series of anticholinergic drugs, dopamine agonists, 7- methylxanthine, and intraocular pressure-lowering drugs.Conclusion: Results highlight the efficacy of atropine in myopia treatment with minimal side effects. Anticholinergic medications, such as atropine, have demonstrated efficacy in managing the progression of myopia with a reduced incidence of adverse effects. The emphasis is placed on achieving better long-term effectiveness and minimizing the rebound effect after treatment is stopped. Furthermore, participating in outdoor activities and reducing eye strain are proven strategies for preventing myopia.","PeriodicalId":10805,"journal":{"name":"Current drug targets","volume":" ","pages":"382-393"},"PeriodicalIF":3.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143001584","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Assessing Anti-Acne Potentials Via In vitro, Ex vivo, and In vivo Models: A Comprehensive Approach. 通过体外，离体和体内模型评估抗痤疮潜力：一种全面的方法。

IF 3 4区医学

Current drug targets Pub Date : 2025-01-01 DOI: 10.2174/0113894501335548250123072644

Ravi Goyal, Gurpreet Kaur, Deepinder Singh Malik, Sachin Singh, Kamal Dua, Deependra Singh, Thakur Gurjeet Singh

{"title":"Assessing Anti-Acne Potentials Via In vitro, Ex vivo, and In vivo Models: A Comprehensive Approach.","authors":"Ravi Goyal, Gurpreet Kaur, Deepinder Singh Malik, Sachin Singh, Kamal Dua, Deependra Singh, Thakur Gurjeet Singh","doi":"10.2174/0113894501335548250123072644","DOIUrl":"10.2174/0113894501335548250123072644","url":null,"abstract":"Acne vulgaris is the 8th most commonly prevailing skin disorder worldwide. Its pervasiveness has been predominant in juveniles, especially males, during adolescence and in females during adulthood. The lifestyle and nutrition adopted have been significantly reported to impact the occurrence and frequency of acne. It typically occurs over the regions of the forehead, upper chest, and back of the body, which are regions with high proportions of active sebaceous follicles. The market today is flooded with the pool of anti-acne medications (oral, topical/systemic) that contain either a single therapeutic agent or a blend targeting multiple pathological pathways. However, the clinical applicability of these preparations is limited due to formulation stability, drug penetrability, and targeting, the incidence of secondary effects, antibiotic resistance, etc. Moreover, the effectiveness of the former therapies varies as per the type and severity of acne. Therefore, it is necessary to extensively research skin physiology under normal and diseased conditions so that newer, safer, and more effective medications can be devised. Moreover, their safety and efficacy should be validated by employing various acne models, and their comparative profiling should be done with standard marketed anti-acne preparations. Acne models assist to uncover the complex disease pathogenesis and identify the potential targets for therapeutic interventions. This review is an attempt to highlight varied in vitro, ex vivo, and in vivo testing procedures done to assess drug efficacy, track disease progression, and compare test substances with existing treatments. By presenting a unified approach to acne modeling, this review will assist researchers in selecting the most appropriate model for their specific research goals, helping them to generate valuable and reproducible data to support the development of effective acne therapies.","PeriodicalId":10805,"journal":{"name":"Current drug targets","volume":" ","pages":"435-453"},"PeriodicalIF":3.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143063883","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0